Journals / Türk Biyokimya Dergisi / 2017 / Cilt: 42 - Sayı: 2

Proteomic analysis of erythropoietininduced changes in neuron-like SH-SY5Y cells

Eritropoetin'in Nöron Benzeri SH-SY5Y Hücrelerinde İndüklediği Değişikliklerin Proteomik Analizi

Pages
213–221
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Levels of 22 protein species were altered by both of the incubation periods (24 h and 48 h) Conclusion: Overall, our results suggest that EPO mainly affects protein species in glucose metabolism, protein and RNA metabolism, cytoskeletal proteins, and mitochondrial protein species.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Erythropoietin (EPO) is widely used for treatment of anemia associated with different diseases; however, its adverse effects limit its use in clinical practice.
📊
Key Findings & Data:In this study, we used a proteomics approach to identify how EPO treatment modifies the cellular proteome.Methods: SH-SY5Y neuroblastoma cells were used as the model system to analyze the effects of EPO treatment at different time points (24 h and 48 h).
💡
Conclusion & Impact:Levels of 22 protein species were altered by both of the incubation periods (24 h and 48 h) Conclusion: Overall, our results suggest that EPO mainly affects protein species in glucose metabolism, protein and RNA metabolism, cytoskeletal proteins, and mitochondrial protein species.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Erythropoietin (EPO) is widely used for treatment of anemia associated with different diseases; however, its adverse effects limit its use in clinical practice. Therefore, understanding the effects of EPO at the molecular and cellular level is crucial to adjust treatment regimes, and to develop non-hematopoietic EPO derivatives. In this study, we used a proteomics approach to identify how EPO treatment modifies the cellular proteome.Methods: SH-SY5Y neuroblastoma cells were used as the model system to analyze the effects of EPO treatment at different time points (24 h and 48 h). Proteomic analysis revealed changes in 74 proteins after EPO treatment. Following proteomics analysis, Reactome pathway analysis were carried out to identify the affected cellular pathways.Results: According to results, EPO alters the levels of 74 protein species (40 were increased, 34 were decreased). The levels of 35 proteins were changed by 24 h EPO incubation, whereas 17 protein species were altered by 48 h EPO incubation. Levels of 22 protein species were altered by both of the incubation periods (24 h and 48 h) Conclusion: Overall, our results suggest that EPO mainly affects protein species in glucose metabolism, protein and RNA metabolism, cytoskeletal proteins, and mitochondrial protein species.

Özet

Giriş ve Amaç: Eritropoetin (EPO) çeşitli hastalıklar ile ilişkili aneminin tedavisinde yaygın kullanılmaktadır, ancak yan etkileri nedeniyle klinikteki kullanımı sınırlıdır. Bu nedenle, tedavi rejimlerini düzenlemek ve hematopoetik olmayan EPO derivelerini geliştirmek için EPO'nun moleküler ve hücresel düzeydeki etkilerini anlamak çok önemlidir. Bu çalışmada, proteomik yaklaşımla EPO tedavisinin hücresel proteomları nasıl etkilediğini tanımlamayı amaçladık.Yöntem ve Gereçler: EPO'nun farklı zamanlardaki (24 h ve 48 h) etkisini analiz etmek için sistem model olarak SH-SY5Y nöroblastom hücreleri kullanıldı. EPO tedavisinden sonra değişiklik izlenen 74 protein proteomik analiz ile gösterildi. Proteomik analizden sonra yapılan Reaktom Yolak Analizi ile de etkilenmiş olan hücresel yolaklar tanımlandı.Bulgular: EPO 74 protein türünün düzeyini değiştirmiştir (40'ı artmış, 34'ü azalmış). 24 saatlik EPO inkübasyonu sonunda 35 proteinin düzeyi değişmiş, 48 saatlik EPO inkübasyonu sonunda ise 17 proteinin düzeyi değişmiştir. 22 protein türünün düzeyi ise her iki inkübasyon süresinde de değişmiştir (24 h ve 48 h).Tartışma ve Sonuç: EPO'nun başlıca glukoz metabolizmasındaki, protein ve RNA metabolizmasındaki protein türlerini, hücre iskeleti proteinlerini ve mitokondrial protein türlerini etkilediği gösterilmiştir

🔖

Cite This Article

GENÇ, K. K., ERBAYRAKTAR, Z., GENÇ, Ş., ÖNKAL, Z. (2022). Proteomic analysis of erythropoietininduced changes in neuron-like SH-SY5Y cells. Türk Biyokimya Dergisi, Cilt: 42 - Sayı: 2, 213–221. https://ajindex.com/articles/621304

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988;71:524–7
  2. Jelkmann W. Regulation of erythropoietin production. J Physiol 2011;589:1251–8
  3. Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995;92:3717–20
  4. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998;52:235–49
  5. Yu X, Shacka JJ, Eells JB, Suarez-Quian C, Przygodzki RM, Beleslin-Cokic B, et al. Erythropoietin receptor signalling is required for normal brain development. Development 2002;129:505–16
  6. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, et al. Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin Sci (Lond) 2002;103:275–82
  7. Ponce LL, Navarro JC, Ahmed O, Robertson CS. Erythropoietin neuroprotection with traumatic brain injury. Pathophysiol 2013;20:31–8
  8. Celik M, Gökmen N, Erbayraktar S, Akhisarogu M, Konakci S, Ulukus C, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 2002;99:2258–63
  9. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98:4044–9
  10. Rarick MU, Loureiro C, Groshen S, Sullivan-Halley J, Gill PS, Bernstein-Singer M, et al. Serum erythropoietin titers in patients with human immunodeficiency virus (HIV) infection and anemia. J Acquir Immune Defic Syndr 1991;4:593–7
  11. Revicki DA, Brown RE, Henry DH, McNeill MV, Rios A, Watson T. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr 1994;7:474–84
  12. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatinassociated anemia: a randomized, double-blind trial with placebo. J Clin Oncology 1994;12:1058–62
  13. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994;84:997–1004
  14. Nemoto T, Yokota N, Keane WF, Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 2001;59:246–51
  15. Cazzola M, Mercurial